InflaRx N.V.
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
IFRX | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL0012661870
- LEI:
- Country:
- United States of America
- Address:
- WINZERLAER STR. 2, 7745 JENA
- Website:
- https://www.inflarx.de/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics that target the complement system. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover potent and specific inhibitors for treating life-threatening and debilitating inflammatory diseases with high unmet medical needs. Its lead product, vilobelimab (GOHIBIC), received U.S. FDA Emergency Use Authorization for the treatment of critically ill, hospitalized adults with COVID-19. InflaRx's pipeline includes first-in-class agents targeting various indications, with a focus on immuno-dermatology, including a late-stage program for Pyoderma Gangrenosum.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all InflaRx N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for InflaRx N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for InflaRx N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
